» Sign in / Register

GH-20K - pituitary

Pituitary Growth Hormone-20K

human, recombinant, E. coli

Cat. No. Amount Price (EUR) Buy / Note
PR-427 100 μg 471,50 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 20 kDa

Accession number: P01241

Accession number: P01241

Purity: > 95 % (SDS-PAGE, RP-HPLC)

Form: lyophilised (Pituitary Growth Hormone protein was lyophilised from a 1 mg/ml solution with 0.0045 mM NaHCO3 and pH 10.0)

Solubility: It is recommended to reconstitute and dilute the lyophilised Placental-GH in 0.4% NaHCO3 adjusted to pH 10.0, which can then be further diluted to other aqueous solutions. It is recommended when diluting to below 10 μg/ml that the dilution solution will contain carrier protein (BSA or other) to avoid nonspecific absorption of the hGH to plastic tubes.

Activity: 3 U/mg

The human GH (GH-20K), which is produced in the pituitary by alternative splicing of GH mRNA comprises approximately 6% of all GH in serum and was elevated in patients with active acromegaly. Pituitary growth hormone (GH) plays diverse roles in the promotion of cell growth and metabolism. GH has been shown to influence the development of the immune organ and the function of immune cells. The binding of GH to its receptor causes dimerization of two growth hormone receptors (GHR), which, in turn, initiates the signal transduction in the cell. Recombinant Human GH-20K produced in E. coli is a single, non-glycosylated, polypeptide chain containing 177 amino acids and having a molecular mass of 20.3 kDa. GH-20K is purified by proprietary chromatographic techniques.

Endotoxin: Less than 0.1 ng/μg (IEU/μg) of GH.

Selected References:
Ryu et al. (2000) Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin. J. Immunol. 165:2116.
Murakami et al. (2004) Serum levels of 20 kilodalton human growth hormone (20K-hGH) in patients with acromegaly before and after treatment with octreotide and transsphenoidal surgery. Endocr. J. 51:343.
Hayakawa et al. (2004) Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH. J. Clin. Endocrinol. Metab. 89:1562.
Takahashi et al. (2001) Diabetogenic activity of 20 kDa human growth hormone (20K-hGH) and 22K-hGH in rats. Growth Horm. IGF Res. 11:110.
Asada et al. (2000) Effects of 22K or 20K human growth hormone on lipolysis, leptin production in adipocytes in the presence and absence of human growth hormone binding protein. Horm. Res. 54:203.
Murakami et al. (2000) Twenty-kilodalton human growth hormone (20K hGH) secretion from growth hormone-secreting pituitary adenoma cells in vitro. Endocr. J. 47:563.
Minagawa et al. (2000) Effects of octreotide infusion, surgery and estrogen on suppression of height increase and 20K growth hormone ratio in a girl with gigantism due to a growth hormonesecreting macroadenoma. Horm. Res. 53:157.